Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Terry Opgenorth
Advertisement
Terry Opgenorth, PhD, is the executive in residence life sciences for CSU Ventures.
Articles by Terry Opgenorth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5